Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Long-Term Deferred Tax (2021 - 2025)

Bioventus (BVS) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax fell 35.84% year-over-year to $4.7 million, compared with a TTM value of $4.7 million through Sep 2025, down 35.84%, and an annual FY2024 reading of $4.7 million, changed N/A over the prior year.
  • Long-Term Deferred Tax was $4.7 million for Q3 2025 at Bioventus, roughly flat from $4.7 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $7.4 million in Q3 2024 and bottomed at $481000.0 in Q2 2021.
  • Average Long-Term Deferred Tax over 3 years is $4.3 million, with a median of $4.7 million recorded in 2024.
  • Peak annual rise in Long-Term Deferred Tax hit 31.07% in 2025, while the deepest fall reached 35.84% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $481000.0 in 2021, then skyrocketed by 886.49% to $4.7 million in 2024, then changed by 0.0% to $4.7 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for BVS at $4.7 million in Q3 2025, $4.7 million in Q2 2025, and $4.7 million in Q1 2025.